"After a national search spanning several years, the Weill Department of Medicine (WDOM) is pleased to announce that Dr. Manuel Hidalgo will serve as Chief of the Division of Hematology and Medical Oncology effective June 1, 2019. Recruited from Harvard Medical School, Dr. Hidalgo is currently the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematology/Oncology, as well as the Clinical Director of the Rosenberg Clinical Cancer Center, at Beth Israel Deaconess Medical Center in Boston. He also serves as the Deputy Associate Director for Clinical Sciences at the Dana-Farber/Harvard Cancer Center in Boston.
A premier investigator in the areas of translational and clinical drug development, Dr. Hidalgo has been at the helm of the early clinical development of more than 50 new anticancer agents. Among these agents, he led erlotinib, temsirolimus, and nab-paclitaxel development which are now FDA approved for the treatment of cancer. Nationally and internationally recognized, Dr. Hidalgo is an authority on pancreatic cancer and has published more than 220 articles in the top tier peer-reviewed journals. His immediate goal is to incorporate immune treatment approaches, both in preclinical models and clinical studies, for pancreatic cancer. Dr. Hidalgo’s research funding includes The National Cancer Institute, and he was the recipient of a European Research Council advanced grant. His interests in translational and clinical anticancer drug development began at The University of Texas Health Science Center at San Antonio (UTHSCSA) in San Antonio, Texas, followed by work at Johns Hopkins where he pioneered the development of PDX models (mouse avatar) models for metastatic PDAC."
News 
Market Data 
Discover 
AI
